Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer
OwnerPaul E. Hoyle, Zhiwan Dong +4inventors
InventorsPaul E. Hoyle, Zhiwan Dong, Thomas Condamine, Nithya Srinivasan, John E. Janik, Kevin N. Heller
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a combination therapy which comprises: (i) an active agent that binds PD-1 (e.g., an anti-PD-1 antibody), (ii) an active agent that binds TIM-3 (e.g., an anti-TIM-3 antibody), and/or (iii) an active agent that binds LAG-3 (e.g., an anti-LAG-3 antibody). The present disclosure provides pharmaceutical compositions thereof, uses thereof, and methods of treatment which include administering the combination therapy to a subject, including methods of treating cancer.
Claims44
A method for treating cancer in a human subject in need thereof, the method comprising administering to the subject at least two of:
- (i) about 375-500 mg of an anti-PD-1 active agent once every three weeks or four weeks;
- (ii) about 400-1000 mg of an anti-TIM-3 active agent once every two weeks, three weeks, or four weeks;
- and (iii) about 350-750 mg of an anti-LAG-3 active agent once every two weeks, three weeks, or four weeks.
(canceled)
A combination therapy comprising at least two of:
- (i) about 375-500 mg of an anti-PD-1 active agent;
- (ii) about 400-1000 mg of an anti-TIM-3 active agent;
- and (iii) about 350-750 mg of an anti-LAG-3 active agent.
7-33. (canceled)
A kit for treating a cancer in a human subject in need thereof, the kit comprising at least two of:
- (i) about 375-500 mg of an anti-PD-1 active agent;
- about (ii) 400-1000 mg of an anti-TIM-3 active agent;
- and (iii) about 350-750 mg of an anti-LAG-3 active agent;
- and instructions to administer the anti-PD-1 active agent once every three weeks or four weeks and to administer the anti-TIM-3 and anti-LAG-3 active agents once every two weeks, three weeks, or four weeks.
35-38. (canceled)
(canceled)
43-45. (canceled)
(canceled)
52-56. (canceled)
(canceled)
63-67. (canceled)
Dependencies are inferred from the claim text.